Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram.
The drug will be produced at Nesher’s facility located at St Louis, US. Nystatin is an anti-fungal drug used to treat skin infections caused by yeast, a company statement said.